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Summary
 
We tested for antigen recognition and T cell receptor (TCR)–ligand binding 12 peptide deriv-
ative variants on seven H-2K
 
d
 
–restricted cytotoxic T lymphocytes (CTL) clones specific for a
bifunctional photoreactive derivative of the 
 
Plasmodium berghei
 
 circumsporozoite peptide 252–
260 (SYIPSAEKI). The derivative contained iodo-4-azidosalicylic acid in place of PbCS S-252
and 4-azidobenzoic acid on PbCS K-259. Selective photoactivation of the N-terminal photo-
reactive group allowed crosslinking to K
 
d
 
 molecules and photoactivation of the orthogonal
group to TCR. TCR photoaffinity labeling with covalent K
 
d
 
–peptide derivative complexes
allowed direct assessment of TCR–ligand binding on living CTL. In most cases (over 80%)
cytotoxicity (chromium release) and TCR–ligand binding differed by less than fivefold. The
exceptions included (
 
a
 
) partial TCR agonists (8 cases), for which antigen recognition was five-
tenfold less efficient than TCR–ligand binding, (
 
b
 
) TCR antagonists (2 cases), which were not
recognized and capable of inhibiting recognition of the wild-type conjugate, (
 
c
 
) heteroclitic ag-
onists (2 cases), for which antigen recognition was more efficient than TCR–ligand binding, and
(
 
d
 
) one partial TCR agonist, which activated only Fas (CD95), but not perforin/granzyme-
mediated cytotoxicity. There was no correlation between these divergences and the avidity of
TCR–ligand binding, indicating that other factors than binding avidity determine the nature of
the CTL response. An unexpected and novel finding was that CD8-dependent clones clearly
incline more to TCR antagonism than CD8-independent ones. As there was no correlation
between CD8 dependence and the avidity of TCR–ligand binding, the possibility is suggested
that CD8 plays a critical role in aberrant CTL function.
 
C
 
D4
 
1
 
 and CD8
 
1
 
 T lymphocytes recognize antigenic
peptides bound to MHC molecules on APC or target
cells by their 
 
a
 
/
 
b
 
 TCR (1). TCR per se have no signaling
capabilities but are associated with CD3 components and 
 
z
 
chains, which mediate TCR signaling (1, 2). In addition, the
coreceptors CD4 or CD8 are associated with the src ty-
rosine kinase p56
 
lck
 
, which plays a critical role in T cell ac-
tivation (1, 2). In normal T cell activation, intercellular TCR–
ligand interactions promote phosphorylation of 
 
z
 
 chains,
which then bind the tyrosine kinase ZAP-70, leading to
the activation of the ZAP-70–NFAT pathway (1, 2). As
originally observed by Allen and coworkers, amino acid
substitutions in antigenic peptides can result in aberrant TCR
signaling, i.e., altered lymphokine production, lack of cell
proliferation, or total anergy of the T cells (3–5). Subse-
quent studies by several groups indicated that aberrant T cell
activation is a general phenomenon and can be observed on
T cell hybridomas, CD4
 
1
 
 and CD8
 
1
 
 T cells, and is not
limited to peptide modification, but can also occur upon
mutations of MHC molecules (6–8).
As to the mechanism, it has been shown that TCR an-
tagonists give rise to monophosphorylation of 
 
z
 
 chains,
which fail to bind and activate ZAP-70, thus perturbing
the ZAP-70–NFAT pathway of T cell activation (4, 9, 10).
Two different concepts have been put forward to explain
these phenomena. According to the first, ligand modifica-
tion results in accelerated dissociation of TCR–ligand com-
plexes, which implies shorter TCR ligation times, resulting
in changes of the size and/or composition of clusters of
TCR and associated signaling molecules (11–13). Alterna-
tively, according to the second concept, ligand modifica-
tions confer via the TCR conformational changes, which
qualitatively alter the signaling by TCR-associated mole-
cules (8, 14). Evidence supporting both concepts has been
reported, but it is not clear whether either of these con-
cepts explains these phenomena. Actually, there are indica-
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tions suggesting that there may be no unifying principle for
aberrant TCR signaling. For example, it has been shown in
several systems that TCR antagonists require large molar
excesses to efficiently inhibit T cell responses of the wild-
type ligand (3, 6, 9, 13). In contrast, other studies indicated
that antagonists can effectively inhibit CTL responses at very
low concentrations, which according to these reports al-
lows fast mutating viruses to escape immune recognition
(15, 16).
There exist other forms of aberrant TCR signaling as
well, such as heteroclitic T cell responses (e.g., a ligand
modification increases T cell response) (17) or T cell anergy
induced by TCR agonists in the absence of a costimulatory
signal (4). Heteroclitic T cell responses have been attrib-
uted to increased MHC–peptide binding or TCR–ligand
binding (17). However, as the latter has not been directly
measured, it cannot be excluded that, actually, the effi-
ciency of TCR signaling was increased. Moreover, for
CTL responses peptide variants have been described that
activate Fas, but not perforin/granzyme-mediated cytotox-
icity (18, 19). These studies suggest that selective activation
of Fas-mediated apotosis may play a role in eliminating self-
reactive CTL. While the signaling pathway leading to Fas
ligand expression is emerging (20, 21), it is not clear how it
can be selectively activated via the TCR.
A major difficulty in studying aberrant TCR signaling
consists in accurately controlling and measuring key param-
eters that initiate signaling, such as MHC–peptide interac-
tions, TCR–ligand binding, kinetics and the contribution
of the coreceptor to TCR–ligand binding. Although differ-
ent reliable in vitro assays exist to measure MHC–peptide
interactions, vigorous control of MHC–peptide binding on
living cells under physiological conditions is complicated
by dissociation of MHC–peptide complexes (22, 23). As to
the assessment of TCR–ligand interactions, a direct TCR–
ligand binding assay has been introduced, in which radiola-
beled soluble ligand was incubated with CTL and cell-asso-
ciated ligand measured after separation of unbound ligand
(24). More recently, soluble TCR and ligand molecules
have been used in binding assays based on plasmon reso-
nance (13, 25, 26). Although this assay is very precise for
high affinity TCR–ligand interactions, detection problems
were encountered when studying low affinity ligand vari-
ants. In addition, this assay does not take into account fac-
tors that influence TCR–ligand interactions on living cells,
such as the coreceptor or TCR downmodulation (27, 28).
We have previously introduced a system that allows as-
sessment of TCR–ligand interactions on living cells by
TCR photoaffinity labeling (23, 27, 29). To this end, the
 
Plasmodium berghei
 
 circumsporozoite peptide PbCS 252–
260 (SYIPSAEKI) was modified by replacing S-252 with
photoreactive iodo-4-azidosalicylic acid (
 
IASA
 
)
 
1
 
 and con-
jugation of the TCR contact residue K-259 with 4-azido-
benzoic acid (
 
ABA
 
). Seven K
 
d
 
-restricted CTL clones were
derived from mice immunized with this conjugate. They
recognized this peptide derivative and the one lacking the
 
IASA
 
 group, but not the derivative lacking the 
 
ABA
 
 group
(29). These clones exhibited all the hallmarks of antigen
recognition by conventional CTL, but had the unique fea-
tures that the peptide derivative can be covalently attached
to K
 
d
 
 molecules by selective photoactivation of the 
 
IASA
 
group and that TCR–ligand interactions can be assessed by
TCR–photoaffinity labeling (23, 29). The TCR photoaf-
finity labeling with soluble ligand directly reflected TCR–
ligand binding and its dependence on CD8 (23, 27).
In the present study, we tested 12 variants of this peptide
derivative on seven CTL clones for antigen recognition (chro-
mium release assay) and TCR–ligand binding by TCR
photoaffinity labeling with soluble ligand. In 80% of the
cases TCR–ligand binding and antigen recognition corre-
lated well. Among the exceptions (
 
>
 
fivefold divergences
between these two parameters), the most frequent cases
were partial agonists for which TCR–ligand binding was
more efficient than antigen recognition. However, cases
in which the recognition was more efficient than TCR–
ligand binding were observed as well. Only two antagonists
were found, e.g., derivatives that were not recognized and
could inhibit the recognition of the wild-type epitope. Re-
markably, the relative efficiency of recognition of epitope
variant did not correlate with TCR–ligand binding avidity.
Data are also presented indicating that CD8-dependent
clones are more susceptible to TCR antagonism than CD8-
independent ones, suggesting that CD8 can interefere with
CTL activation.
 
Materials and Methods
 
Synthesis and Characterization of Photoreactive PbCS Peptide Deriv-
atives.
 
Chemicals for peptide and conjugate synthesis were ob-
tained from Sigma Chemie (Buchs, Switzerland), Neosystems (Stras-
bourg, France), and Bachem Finechemical AG (Bubendorf,
Switzerland). The synthesis, purification, and analysis of 
 
IASA
 
-
YIPSAEK(ABA)I and its derivatives were performed as described
(23, 29, 30). In brief, all conjugates were synthesized on an ABI
431 peptide synthesizer (Applied Biosystems Instruments, Foster
City, CA) using F
 
moc
 
 for transient NH
 
2
 
-terminal protection. K(
 
ABA
 
)
was incorporated as Fmoc-K(
 
ABA
 
)-OH and Y as F
 
moc
 
-Y(PO
 
3
 
H
 
2
 
).
After blocking the NH
 
2
 
 terminus with 4-azidosalicylic acid
(
 
ASA
 
), the conjugates were deprotected and cleft from the resin.
Purification was by reverse-phase HPLC on a C-18 column (1 
 
3
 
25 cm, 5-
 
m
 
m particle size, Marcherey & Nagel, Oensingen, Swit-
zerland) using a Waters 600 E HPLC system and an in-line 1000 S
diode-array photospectrometer (Applied Biosystems Instruments,
Foster City, CA). The column was eluted by a linear gradient of
acetonitrile in 0.01% trifluoroacetic acid rising within 1 h from
0–75%. The purified conjugates containing 
 
ASA
 
 and Y(PO
 
3
 
H
 
2
 
)
were iodinated with 
 
125
 
I iodine (New England Nuclear, Boston,
MA; specific radioactivity 
 
z
 
2,000 Ci/mMol) or nonradioactive
iodine followed by enzymatic dephosphorylation and purified by
HPLC. The elution times were as follows: 
 
IASA
 
–YIPSAEK
(
 
ABA
 
) I 
 
z
 
44 min; I254A, 
 
z
 
41 min; P255A, 
 
z
 
44 min; S256A,
 
z
 
45 min; E258A, 
 
z
 
46 min; K259(
 
ASA
 
), 
 
z
 
43 min; K259(
 
BA
 
),
 
z
 
42 min; P255L, 
 
z
 
48 min; P255S, 
 
z
 
43 min; P255N, 
 
z
 
44 min;
P255D, 
 
z
 
43 min; P255K, 
 
z
 
41 min; and P255H, 
 
z
 
42 min. All con-
 
1
 
Abbreviations used in this paper:
 
 ABA, 4-azidobenzoic acid; ASA, azidosali-
cylic; IASA, iodo-4-azidosalicylic acid.
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jugates displayed the expected spectra and molecular mass (as assessed
on a LDI 7000 mass spectrometer; Linear Scientific, Reno, CA).
 
Cells and Antibodies.
 
The P815 mastocytomas, A20 and A20
Fas
 
2
 
 B lymphomas (31), were maintained in DMEM supple-
mented with FCS (5%) and Hepes (10 mM). The CTL clones
and their culture conditions have been described previously (29).
They were stimulated weekly by irradiated BALB/c splenocytes
and irradiated P815 cells pulsed with 
 
IASA
 
–YIPSAEK(
 
ABA
 
)I in
conditioned medium. Hybridomas producing the mAb used were
obtained from the American Type Culture Collection (ATCC,
Rockville, MD).
 
Cytolytic Assays.
 
51
 
Cr-labeled P815 or A20 cells were used as
targets in a cytolytic assay as described (23, 29). In brief, target
cells (2 
 
3
 
 10
 
3
 
 per well) were incubated in microtiter plates con-
taining threefold dilutions of peptide derivative in DMEM sup-
plemented with FCS (5%) and Hepes (10 mM). CTL (6 
 
3
 
 10
 
3
 
per well) were added after 15 min and after 4 h or 8 h for A20
and A20 Fas
 
1
 
 cells of incubation at 37
 
8
 
C, the 
 
51
 
Cr content of su-
pernatants was determined. The specific lysis was calculated as
100 
 
3
 
 ([experimental 
 
2
 
 spontaneous release]/[total 
 
2 
 
spontane-
ous release]). The relative antigenic activities were calculated by
dividing the concentration of 
 
IASA
 
-YIPSAEK(
 
ABA
 
)I required
for half-maximal lysis, by that required for the variant peptide de-
rivatives. The K
 
d
 
 competitor activity, reflecting K
 
d
 
 binding of
the test compounds, was assessed in a recognition-based com-
petition assay and normalized relative to the one of 
 
IASA
 
-YIP-
SAEK(
 
ABA
 
)I, which was defined as 1, as described (23, 29). For
sake of comparison, the relative antigenic activities of the com-
pounds were normalized by dividing the relative antigenic activ-
ity by the corresponding relative K
 
d
 
 competitor activities (29). To
test the ability of the conjugates to inhibit recognition of 
 
IASA
 
–
YIPSAEK(
 
ABA
 
)I, P815 target cells were labeled with 
 
51
 
Cr in the
presence of 20–120 pM of 
 
IASA
 
-YIPSAEK(
 
ABA
 
)I for 1 h at
37
 
8
 
C. The cells were irradiated for 20 s at 
 
>
 
350 nm with a 3,000
W Supuva Sun 3,000 UV irradiator (Mutzhas AG, Luzern, Swit-
zerland). The cells were incubated with 10 
 
m
 
M PbCS 252–260
peptide for 30 min and washed again (three times), and resus-
pended at 2 
 
3
 
 10
 
5
 
 cells/ml. Aliquots (10
 
4
 
 cells in 50 
 
m
 
l) were
plated in round-bottomed microtiter plates containing threefold
dilutions of the test compound. After preincubation for 30 min at
37
 
8
 
C, CTL (3 
 
3
 
 10
 
4
 
 in 50 
 
m
 
l) were added and the plates incu-
bated for 4 h at 37
 
8
 
C. The suboptimal concentration of 
 
IASA
 
–
YIPSAEK(
 
ABA
 
)I antigenic peptide was dosed such that a specific
lysis of 20–50% was obtained in the absence of a test compound.
Spontaneous 
 
51
 
Cr release was 
 
<
 
5% in all experiments. Each ex-
periment was performed in triplicates and repeated at least twice.
 
K
 
d
 
 and TCR Photoaffinity Labeling.
 
All photoaffinity labeling
procedures were performed essentially as described (23, 29, 30).
In brief, purified soluble K
 
d was incubated with 125I-labeled pep-
tide derivatives and b2-microglobulin (Sigma) for 2 h at ambient
temperature. After UV irradiation at >350 nm, PbCS peptide
252–260 was added (10 mM) and after overnight incubation at
48C the covalent Kd-peptide derivative complexes were purified
by gel filtration FPLC. Cloned CTL (1-ml aliquots containing
1 3 106 cells) were incubated with Kd–peptide derivative com-
plexes (3–10 3 106 cpm/incubation) for 3 h at 0–48C. After UV
irradiation at 312 6 40 nm with a 90 W mercury fluorescence
lamp (Bioblock Scientific, Illkirch, France) for 30 s the cells were
washed, detergent lysed, and the immunoprecipitated TCR-
ligand complexes analyzed by SDS-PAGE.
Immunoprecipitation, Gel Electrophoresis, and Quantitative Analysis.
Immunoprecipitation with the anti-TCR mAb H57-597 and
SDS PAGE analysis (10%, reducing conditions) were performed
following published procedures (23, 29, 30). The dried gels were
Table 1. Kd Binding of IASA-YIPSAEK (ABA) I Variants Under Study
No. Name Sequence
Relative Kd
Competitor Activity*
1 wt IASA Y I P S A E K (ABA) I 1
2 1254A 2 2 A 2 2 2 2 2 2 0.2
3 P255A 2 2 2 A 2 2 2 2 2 0.3
4 S256A 2 2 2 2 A 2 2 2 2 0.2
5 E258A 2 2 2 2 2 2 A 2 2 0.7
6 K259 (ASA) 2 2 2 2 2 2 2 K (ASA) 2 0.5
7 K259 (BA) 2 2 2 2 2 2 2 K(BA) 2 0.6
8 P255L 2 2 2 L 2 2 2 K (ABA) 2 0.1
9 P255S 2 2 2 S 2 2 2 2 2 0.2
10 P255N 2 2 2 N 2 2 2 2 2 0.2
11 P255D 2 2 2 D 2 2 2 2 2 0.07
12 P255K 2 2 2 K 2 2 2 2 2 0.1
13 P255H 2 2 2 H 2 2 2 2 2 0.2
*The relative Kd competitor activity indicates the ability of a test compound to bind to Kd. It was determined in a recognition based compeitition as-
say and was normalized relative to one of IASA-YIPSAEK (ABA) (see Materials and Methods).
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exposed to Kodak 5 XAR x ray films in Kodak Super Rapid
(Kodak x-Omatic; Rochester, NY) cassettes at 2808C or evalu-
ated by phospho-imaging using a Phospho Imager SF and Image
Quant software (Molecular Dynamics). Standard deviations were
calculated according to the Student’s t test from data of at least
three different experiments, each performed in triplicates. The
detection limit of TCR photoaffinity labeling was z1% for
clones S4, S14, S17, and T1, 5% for S18 and S1, and 10% for S15.
Relative TCR photoaffinity labeling was calculated by dividing
the labeling intensity of the ligand variant by the one of the wild-
type ligand. The TCR binding of Kd–“125IASA”-YIPSAEK(BA)I
was titrated in threefold dilution up to a 50-fold molar excess.
The concentration required for 50% inhibition was determined
by extrapolation and used to calculate the relative TCR binding.
TCR-Ligand Binding Assay. CTL were incubated with cova-
lent soluble radiolabeled Kd–peptide derivative complexes as de-
scribed above. After 3 h of incubation, the cells were centrifuged
in 400-ml tubes (10–15 s, Beckman Microfuge; Beckman Instrs.,
Palo Alto, CA) through a layer of silicon (84%) and paraffin oil
(16%) to separate cell-bound and free Kd–peptide complex, count-
ing each in a Packard Gamma Counter. Nonspecific binding of
the soluble ligand complex was 20–30% observed in the presence
of anti-Kd mAb 20-8-4S (10 mg/ml). Percentage of binding was
calculated by dividing the value of the corresponding ligand com-
plex by the one of Kd-IASA-YIPSAEK(ABA)I, which was de-
fined as 100%.
Results
Photoreactive Peptide Derivative Variants Under Study.
To assess the correlation between TCR–ligand binding
and antigen recognition by cloned CTL, we examined 12
variants of the PbCS peptide derivative IASA-YIPSAEK
(ABA)I listed in Table 1. Four of these variants contained
single Ala substitutions in positions known to be potentially
relevant for antigen recognition but not Kd binding (32).
Two further variants contained modifications of the ABA
group, namely K259(BA), which lacks the azido substitu-
ent and K259(ASA), which had an additional hydroxy sub-
stituent. The remaining six variants contained L, S, N, D,
K, or H in place of PbCS P-255. The ability of these con-
jugates to bind to Kd was assessed in a recognition based
competition assay and the Kd competitor activities were
normalized to the one of IASA-YIPSAEK(ABA)I, which
was defined as 1. The relative Kd competitor activities var-
ied between 0.07 (P255D) and 0.7 (E258A), e.g., bound to
Kd 14–1.4-fold less efficiently than IASA-YIPSAEK (ABA)I.
Antigen Recognition by S14 CTL. The recognition of
the different conjugates by cloned CTL was assessed in a
51Cr release cytolytic assay. As shown for a representative
experiment in Fig. 1 A, half-maximal lysis of P815 cells by
S14 CTL was observed at about 8 3 10212 M IASA-YIP-
SAEK(ABA)I. The variant P255A showed the same effi-
ciency of recognition, but serine substitution in this posi-
tion (P255S) resulted in an z7-fold decrease and aspartic
acid substitution (P255D) in a 2,000-fold decrease. Histi-
dine or leucine substitution (P255H and P255L) obliterated
recognition by S14 CTL. For sake of comparison and as
shown in Fig. 1 B, the normalized antigenic activities were
calculated for the different compounds from the antigenic
activities (concentrations required for half-maximal lysis) and
the corresponding relative Kd competitor activities (Table 1)
(see Materials and Methods).
TCR–Ligand Binding on S14 CTL. The same peptide
derivatives were radiolabeled and photocross-linked to sol-
uble monomeric Kd. These complexes were incubated with
cloned S14 cells and after photoactivation of the ABA group,
the immunoprecipitated TCR were analyzed by SDS-PAGE
under reducing conditions and autoradiography. As shown
for a representative experiment in Fig. 2 A, the trimolecu-
lar complexes (MHC–peptide–TCR a or b chain) mi-
grated with an apparent Mr of z90 kD. Intense TCR pho-
toaffinity labeling was observed in the case of the wild-type
ligand (Fig, 2 A, lane 1), which was abolished in the pres-
ence of the anti-Kd mAb 20-8-4S, which blocks Kd–TCR
interactions (lane 2) (29). Strong labeling was also observed
with the ligand variants Kd-P255A and Kd-P255S (Fig. 2 A,
lanes 3 and 4), whereas the variants Kd-P255D and Kd-
P255L produced only trace labeling (lanes 5 and 6). No la-
beling was detectable with the ligand Kd-P255H (Fig. 2 A,
lane 7).
For quantification, the autoradiograms were evaluated
by phospho-imaging. The reading for the wild-type ligand
was defined as 100% and the readings for the other ligands
Figure 1. Recognition of IASA-YIPSAEK(ABA)I and variants by
cloned S14 CTL. (A) 51Cr-labeled P815 cells were incubated with S14
cells in the presence of the indicated concentrations of IASA-YIP-
SAEK(ABA)I (d), P255A (s), P255S (m), P255D (r), P255L (.) and
P255H (j) at an E/T ratio of 3:1. After 4 h of incubation the specific ly-
sis was determined from the relased chomium. (B) The relative antigenic
activities calculated from A were normalized with the relative Kd compet-
itor activities (Table 1) (see Materials and Methods). By definition, the
normalized antigenic activity of IASA-YIPSAEK(ABA)I is 1.
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expressed relative to this value (Fig. 2 B). To assess whether
TCR photoaffinity labeling truthfully reflects the actual
TCR–ligand binding, S14 cells were incubated likewise with
the same ligands and the cell-associated ligand was sepa-
rated from free ligand by spinning the cells through oil gra-
dients. As shown in Fig. 2 C, essentially the same binding
pattern was observed, indicating that for a given clone
TCR photoaffinity labeling is proportional to the TCR–
ligand binding. While the TCR photoaffinity labeling assay
had no detectable background, the background in the di-
rect binding assay was high (z30%) (Fig. 2, B and C). For
this reason the detection limit in the TCR photoaffinity la-
beling assay was considerably lower (z1% versus 30%).
Recognition of Six IASA-YIPSAEK(ABA)I Variants by
Seven CTL Clones. We tested the first six variants of
IASA-YIPSAEK(ABA)I (Table 1) for recognition on seven
IASA-YIPSAEK(ABA)I-specific CTL clones. As shown in
Fig. 3 A, the normalized relative antigenic activities of the
variants I254A, P255A, and S256A were in the range of 0.1
to 6 (e.g., were recognized between 10-fold less to 6-fold
more efficiently than IASA-YIPSAEK(ABA)I), indicating
that none of these substitutions dramatically affected the
antigen recognition by these clones. Conversely, the vari-
ant E258A was efficiently recognized only by clones S1,
S4, S15, and S18, but only inefficiently by clone S14 and
not detectably by clones S17 and T1. Of the K259(ABA)
variants, K259(ASA) was efficiently recognized by all clones,
except by clone S15, which recognized this variant only
partially (e.g., the specific lysis never exceeded 30%). An
even lower plateau of lysis was observed for the variant
IASA-YIPSAEK(IASA)I (data not shown). Conversely, the
variant K259(BA) was efficiently recognized only by clones
S4, S17, S18, inefficiently by clones S1, S15, and T1
clones, and not detectably by clone S14. More drastic
modifications of the K(ABA) side chain, such as shortening
by one methylene group, deletion of the ABA group, or
alanine substitution obliterated antigen recognition and
TCR–ligand binding (reference 29; data not shown).
TCR Photoaffinity Labeling by Six Ligand Variants on Seven
CTL Clones. We next assessed TCR–ligand binding for
the same peptide derivative variants by TCR photoaffinity
labeling as described for Fig. 3. Because the variants I254A
and K259(ASA) were efficiently recognized by all clones,
except for K259(ASA) by S15 CTL, only this case was
tested. As shown in Fig. 3 A, the normalized TCR photo-
affinity labeling and the normalized antigenic relative anti-
genic activities were less than fivefold different, except for
six cases. For the variants, P255A on clone T1 and S256A
on clone S17 antigen recognition was more efficient than
TCR–ligand binding (eight and fivefold different, respec-
Figure 2. TCR–ligand bind-
ing assessed by TCR photoaffin-
ity labeling and a direct binding
assay. (A) Cloned S14 CTL were
incubated with equal amounts of
radiolabeled soluble covalent com-
plexes of Kd and peptide deriva-
tives IASA-YIPSAEK(ABA)I (lane
1 without and lane 2 with anti-
Kd mAb 20-8-4S), P255A (lane
3), P255S (lane 4), P255D (lane
5), P255L (lane 6), and P255H
(lane 7) at 0–48C, and after UV
irradiation, the immunopreci-
pated TCR–ligand complexes
were analyzed by SDS-PAGE
and autoradiography. (B) The gels
were evaluated by phospho-
imaging and represented as bar
graphs. (C) Alternatively, the
UV irradiation was omitted and
cell-associated and free ligand
were separated by centrifugation
through oil gradients. The cell-
associated radioactivity of wild-
type ligand was defined as 100%
and those of the variant ligands
are expressed in percent. The
mean values and standard devia-
tions were calculated from tripli-
cates.
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tively). The opposite situation was observed for the variant
E258A on clones S4, S14, and S15, for which the normal-
ized antigenic activity was five- to sevenfold lower than the
TCR photoaffinity labeling. Finally, the variant K259(BA)
was not recognized by S14 CTL, but as assessed by inhibi-
tion of S14 TCR photoaffinity labeling (see Materials and
Methods), its Kd complex detectably bound to S14 TCR.
Correlation Between Antigen Recognition and TCR–Ligand
Binding for PbCS P-255 Substituted Peptide Derivative Vari-
ants. From structural analysis of TCR–ligand interactions,
evidence was obtained indicating that P-255 of IASA-YIP-
SAEK(ABA)I is a secondary TCR contact residue for most
of the clones (unpublished data). Therefore, we tested like-
wise six variants containing different amino acids in this
position (Table 1). As shown in Fig. 3 B, these substitutions
dramatically affected the antigen recognition by at least
some of the seven CTL clones. The least dramatic effects
were observed for P255S and the most dramatic ones for
P255H, which was significantly recognized only by S17 CTL.
Testing of the variants in TCR photoaffinity labeling ex-
periments showed that in most cases (36 of 42) TCR–
ligand binding and antigen recognition differed by less than
fivefold. As shown in Fig. 3 B, only in six cases (P255L on
CTL S4, and S14, variant P255S on CTL S17, variant
P255K on CTL S4, and variant P255D on CTL S14) the
two parameters differed by more than fivefold. In all cases
the TCR–ligand binding was more efficient than the anti-
gen recognition.
Variant K259(ASA) on S15 CTL Activates Fas, but Not
Perforin-mediated Cytotoxicity. To find out whether the partial
recognition of variant K259(ASA) by S15 CTL (Fig. 3 A) was
accounted for by Fas-mediated cytotoxicity, antigen recog-
nition experiments were performed by using as target cells
either A20 B lymphoma cells or an A20 variant that lacked
functional Fas (A20 Fas2). As shown for a representative ex-
periment in Fig. 4, A20 cells were efficiently lysed by S15
CTL in the presence of the wild-type peptide derivative, with
half-maximal lysis reached at z2 3 10212 M of IASA-YIP-
SAEK(ABA)I. Conversely, the variant K259 (ASA) was
recognized only partially, with half-maximal lysis of only 13%
observed at about 3 10210 M. Similar results were obtained
on P815 target cells (see Figs. 3 A and 5 C). However,
A20 Fas2 target cells were not detectably lysed in the pres-
ence of this variant, although they were efficiently killed in
the presence of the wild-type epitope (half-maximal lysis at
about 2 3 10211 M) (Fig. 4 B). These results strongly sug-
gest that the low lysis of K259(ASA) sensitized A20 cells
was accounted for essentially by Fas-mediated cytotoxicity,
similarly as has been described in other systems (18, 19).
Variants P255L and K259(BA) Are TCR Antagonists for
S14 CTL. The conjugate variants P255L and K259(BA)
were not recognized by S14 CTL, although their Kd com-
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plexes significantly bound to S14 TCR (see Fig. 3). There-
fore, we examined their ability to inhibit recognition of
IASA-YIPSAEK(ABA)I. To rule out competition of K259
(BA) with the wild-type epitope for Kd binding, we photo-
cross-linked IASA-YIPSAEK(ABA)I to target cell–associ-
ated Kd molecules. As shown for a representative experi-
ment in Fig. 5 A, thus sensitized P815 cells were lysed by
S14 CTL with z22% specific lysis. This lysis was gradually
inhibited in the presence of increasing amounts of IASA-
YIPSAEK(BA)I to z5% specific lysis at .5 3 1028 M of
IASA-YIPSAEK(BA)I. No significant inhibition was ob-
served when the parental PbCS peptide was added, demon-
strating that this inhibition was accounted for by antago-
nism and not by competition on the level of Kd–peptide
binding.
Likewise similar findings were obtained when the variant
P255L was tested, except that a z10-fold higher concen-
tration of P255L was required for maximal inhibition (Fig.
5 B). In contrast, when the variant K259(ASA) was tested
the same way on S15 CTL, no inhibition was observed
(Fig. 5 C). All experiments were performed with target
cells expressing different densities of Kd–“IASA”-YIP-
SAEK(ABA)I complexes, which showed that the inhibition
decreased with increasing degrees of sensitization and van-
ished above 60% specific lysis (data not shown). The same
observation has been made in another system (9). These re-
sults indicate that the variants K259(BA) and P255L were
antagonists for the S14 CTL clone, but that the partial rec-
ognition of K259 (ASA) by the S15 clone (see Fig. 4 C)
was not accounted for by antagonism.
Aberrant TCR Signaling and CD8 Dependence. From Fig. 3,
it emerges that epitope modifications affect antigen recog-
nition and TCR–ligand binding in a clone-specific man-
ner. To find out whether this is accounted for by CD8, we
assessed the CD8 dependence of the clones, as well as the
avidity of their TCR–ligand binding. As shown in Fig. 6,
Figure 3. Antigen recognition and TCR–ligand binding of IASA-YIPSAEK(ABA)I by seven CTL clones. Antigen recognition, as expressed in nor-
malized relative antigenic activities were assessed as described for Fig. 1 and TCR–ligand binding, expressed as normalized TCR photoaffinity labeling, as
described for Fig. 2. The TCR binding of Kd-“125IASA”-YIPSAEK(BA) was assessed as described in Materials and Methods. Shown in gray shaded bars
are cases in which TCR-ligand binding was >fivefold more efficient than antigen recognition; in vertical-striped bars cases in which the antigen recog-
nition was >fivefold more efficient than TCR ligand binding; in diagonal-striped bars cases in which TCR antagonists and in checker-striped bars a partial
agonist exhibiting low plateau (lp) of lysis. (A) Six IASA-YIPSAEK(ABA)I variants were examined, containing either single alanine substitutions of PbCS
residues or modifications of the K(ABA) side chain. (B) Six additional conjugate variants containing L, S, N, D, K, or H in place of PbCS P255 likewise
were tested. The indicated mean values and standard deviations were calculated from at least three independent experiments.
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the recognition of IASA-YIPSAEK(ABA)I by the different
clones was inhibited by the anti-CD8b mAb H35-17 in a
diverse manner. The recognition by the S1, S17, and T1
clones was barely affected, but significantly impaired for
clones S4 and S15 and abolished for clones S14 and S18.
Because anti-CD8 mAb can have diverse effects on CTL,
we repeated these experiments using the anti-CD8a mAb
53.6.72, which binds the other chain of CD8 as well as
Fab9 fragments of this mAb. Essentially the same findings
were obtained (Fig. 6; data not shown), indicating that
clones S14, S17, and T1 are CD8 independent, clones S14,
S15, and S18 are CD8 dependent, and clone S4 is interme-
diate. Interestingly, TCR antagonism was observed mainly
among the CD8-dependent clones (see Figs. 3 and 6).
The TCR–ligand binding avidity of the different CTL
clones was assessed by the TCR–ligand binding assay de-
scribed for Fig. 2 C. As shown in the inserts in Fig. 6, the
highest binding was observed for S4 CTL and was defined
as 100%. The second highest TCR–ligand binding was ob-
served on T1 CTL (80%), followed by clones S14 (40%)
and S17 (30%). Intermediate binding was recorded on
clones S14 and S17, and for clones S1 and S15, the specific
binding was barely above the background. According to
TCR photoaffinity labeling, the weakest binding was ob-
served for S15 CTL (7%), followed by CTL S1 (22%) and
S18 (25%). The bindings avidities correlated poorly with
the observed CD8 dependence, but rather well with the
ability of the CTL clones to recognize the different epitope
modifications (see Figs. 3 and 6). This is probably explained
by that low avidity TCR–ligand interactions are more
likely to be reduced below a critical threshold required for
T cell activation.
Discussion
The availability of CD81 CTL clones that permit direct
assessment of TCR–ligand binding by TCR photoaffinity
labeling, provided an unique opportunity to study in a sys-
tematic manner the correlation between CTL function and
TCR–ligand binding. Whereas correlations between T cell
responses to altered peptide ligands and TCR–ligand bind-
ing have been studied previously with purified recombi-
nant TCR and ligands (13, 25, 26), the present study is
novel in that TCR–ligand binding was measured on living
cells, which takes into account CD8 contributions (27). In
addition, since the study was performed on a family of
Figure 4. S15 CTL recognize variant K259(ASA) only by Fas-medi-
ated cytotoxicity. Cloned S15 CTL were incubated with 51Cr-labeled
A20 (A) or A20 Fas2 cells (B) in the presence of graded concentrations of
IASA-YIPSAEK(ABA)I (closed circles) or IASA-YIPSAEK(ASA)I (open
circles) at an E/T ratio of 3:1 for 8 h.
Figure 5. Recognition of target cells expressing covalent Kd-“IASA”-
YIPSAEK(ABA)I complexes by S14 CTL is inhibited by variants P255L
and K259(BA). Kd molecules on 51Cr-labeled P815 target cells were pho-
tocross-linked with a suboptimal concentration of IASA-YIPSAEK(ABA)I.
After extensive washing the target cells were incubated with CTL S14 (A
and B) or S15 (C) in the presence of the indicated concentrations of pep-
tide PbCS 252-260 (open circles), or peptide variants K259(BA) (closed circle
in A), or P255L (closed circle in B) or K259(ASA) (closed circle in C). The
recognition of the respective conjugate variants on normal 51Cr-labeled
target cells is shown (closed squares). After 4 h, of incubation 51Cr-release
was measured and the specific lysis calculated as described for Fig. 1.
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seven CTL clones of the same origin and the same specific-
ity (29), it also provides insights into clone-specific features
of antigen recognition. By testing 12 variants of the PbCS
peptide derivative IASA-YIPSAEK(ABA)I for antigen rec-
ognition and TCR photoaffinity labeling, we found that
generally there exists a good, though rarely strict, correla-
tion between cytotoxicity and TCR–ligand binding (Fig. 3)
and in only 12 of these 2 parameters diverged by fivefold or
more. Whereas similar findings have been obtained in a
previous study, in which TCR–ligand interactions were
measured with purified TCR and ligand by plasmon reso-
nance (25), another report contends that some 40% of pep-
tide variants were antagonists, e.g., antagonized lysis by three
OVA-specific CTL clones (6). In contrast, we only found
two TCR antagonists (2,4%) (Figs. 3 and 5). This discrep-
ancy may be explained, at least in part, by that in our sys-
Figure 6. CD8 dependence and
avidities of TCR–ligand binding.
The recognition of IASA-YIP-
SAEK(ABA)I by the different
CTL clones was assessed in the
presence or absence of the anti-
CD8b mAb H35-17 or the anti-
CD8a mAb 53.6.72 as described
for Fig. 1. Alternatively, and as
shown in the inserts, the cloned
CTL were incubated in the ab-
sence (closed bars) or presence
(open bars) of anti-Kd mAb 20-
8-4S with Kd-“125IASA”-YIP-
SAEK(ABA)I and the cell-asso-
ciated radioactivity was measured
as described for Fig. 2 C. 100%
refers to the highest degree of
binding, as observed on CTL S4.
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tem, but not in the other, competition of the peptide vari-
ant (antagonist) and the stimulatory peptide (agonist) for
MHC binding was strictly ruled out (Fig. 5). Since at least
some MHC class I–peptide complexes have limited stability
on living cells under physiological conditions, such compe-
tition may give exaggerated positive readings in antagonist
assays, in which peptide variants usually are used in large
excess to the wild-type peptide (Fig. 5; references 6, 9).
If one disregards the cases in which the efficiency of
TCR–ligand binding and antigen recognition differed by
less than 5-fold, as well as the two TCR antagonists, 10 sit-
uations were observed, in which these two parameters di-
verge by up to 10-fold (Fig. 3). These can be grouped in two
categories: (a) the antigen recognition was more efficient
than TCR–ligand binding (2 cases) and (b) conversely, it was
less efficient than TCR–ligand binding (8 cases). The first and
larger group we call partial agonists, though it may contain
partial TCR antagonists, e.g., variants that partially antago-
nize antigen recognition. The second group we call hetero-
clitic agonists, because they activate CTL more efficiently
than expected from their TCR–ligand binding. A similar case
has been observed when measuring TCR–ligand binding
by plasmon resonance (25). Because in most previous stud-
ies on heteroclitic T cell responses TCR–ligand binding
was not directly assessed, it is conceivable that at least some
of the reported heteroclitic T cell responses actually belong
to this category. The only case observed in this study, in
which epitope modification increased both the efficiency
of antigen recognition and TCR–ligand binding relative to
the wild-type epitope, was P255A on S14 CTL (Fig. 3).
This effect, however, was only twofold.
Our data clearly show that there exists no correlation be-
tween the avidity of TCR–ligand binding and the relative
efficiency of antigen recognition. For example, the pep-
tide-derivative variants K259(BA), P255L, P255D, and
E258A bind to S14 TCR with comparable avidities, yet
the former two were antagonists, whereas the latter two
were partial agonists (Fig. 3). Also K259(BA) was a more
potent antagonist for S14 CTL than P255L (Fig. 5), yet its
Kd complex bound to S14 TCR less efficiently than the
one containing P255L (Fig. 3). Moreover, other variants
on other clones exhibited similarly reduced TCR–ligand
binding, but were recognized more efficiently than the
corresponding TCR–ligand binding (i.e., P255S on T1,
and P255H on S17). Even more strikingly, the variant
S256A was recognized sixfold more efficiently by S17 CTL
than the wild-type epitope, whereas the variant P255S was
recognized fivefold less efficiently, yet the TCR–ligand
binding was the same for both variants (Fig. 3).
It has recently been shown that TCR–ligand complexes
with antagonists dissociate faster than those of TCR ago-
nists, but that the corresponding association rates are com-
parable (13). The finding that our two antagonists and most
of the partial agonists displayed significantly reduced TCR–
ligand binding (Fig. 3) is consistent with this. However,
other data are difficult to explain this way. For example, the
finding that the TCR–ligand binding avidity can be the
same for TCR antagonists and partial agonists (see above) ac-
cording to this concept would imply that the correspond-
ing TCR–ligand association rates are significantly different.
Moreover, for clones S15 and S17 partial agonists were
found (E258A and P255S, respectively), which exhibited
TCR–ligand binding equal or better than the wild-type
ligand (Fig. 3). Also, it has been reported that certain viral
CTL epitope mutants can antagonize CTL responses at very
low concentrations, suggesting that these variants too avid-
ily interact with TCR (15, 16). Preliminary results surpris-
ingly indicated that ligands containing partial agonists (i.e.,
variant P255S on CTL S17 or E258A on CTL S4) dissoci-
ate considerably slower from TCR than the wild-type li-
gand, whereas those containing heteroclitic agonist (i.e., var-
iant S256A on CTL S17 or P255A on CTL T1) dissociate
faster (our unpublished results). While these studies need to
be extended, they suggest that the half-life of TCR–ligand
complexes, rather than TCR–ligand binding avidities, are
critical for recognition of epitope variant but that the effi-
ciency of recognition is actually inversely related to the TCR–
ligand dissociation rates. This observation seems best explained
by serial TCR–ligand engagement during CTL–target cell
interaction (28), in that ligands that rapidly dissociate from
TCR interact with TCR more frequently, thus providing
more TCR signaling. However, this relationship is applicable
only as long as TCR–ligand interactions produce normal
TCR signaling and one may expect that if TCR–ligand
dissociations exceed a certain threshold, aberrant TCR sig-
naling will result, as described by Lyonis et al. (13).
However, other factors may also play a role in aberrant
CTL activation. An interesting situation is encountered
where epitope variants can induce only Fas, but not per-
forin mediated cytotoxicity (Fig. 4; references 18, 19). As
both lytic mechanisms are activated by TCR ligation, yet
involve different signaling pathways (20, 21) and TCR an-
tagonism, at least in our system, is ruled out (Fig. 5 C), the
question arises how TCR ligand variants can selectively ac-
tivate the Fas pathway. An interesting observation is that
the anti-CD8b mAb H35-17, but not the anti-CD8a mAb
53.6.72, impaired the recognition of IASA-YIPSAEK(ABA)I
by S15 CTL in a manner similar to the epitope modifica-
tion K259(ASA) (Figs. 4 and 6), suggesting that anti-CD8b
mAb may also selectively inhibit perforin mediated cyto-
toxicity. The role of the coreceptor in aberrant T cell acti-
vation is presently poorly understood. It has been shown
that blocking of CD4 by anti-CD4 mAb can convert a
TCR agonist in an antagonists (34, 35). We made similar
observations in the here-described CD8 systems (our un-
published results). We have previously shown that CD8
considerably strengthens TCR–ligand binding, which, at
least in part, was explained by CD8-mediated decrease of
TCR–ligand dissociation (27). According to the kinetic
proofreading concept (11–13), these observations thus may
be explained by accelerated dissociation of TCR–ligand
complexes.
An interesting finding of the present study is that all
antagonists and partial agonist, except one, were observed
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on CD8-dependent clones (Figs. 3 and 6), suggesting that
CD8 may interfere with CTL activation. The poor corre-
lation between CD8 dependence and avidity of TCR–
ligand binding (Fig. 6), suggests that CD8 dependence is
explained by a requirement of CD8 signaling for CTL acti-
vation, rather than by CD8-mediated increase of TCR–
ligand binding avidity. The same conclusion has been
reached in a different system (33). Studies by Mescher et al.
have clearly demonstrated that CD8 signaling requires CD8
activation, which is induced by TCR/CD3 ligation (36,
37). Moreover, there is ample evidence indicating that
TCR ligation initiates various signaling cascades, and that
TCR ligand modifications can affect these in a diverse
manner (4, 5, 21). Thus, it seems conceivable, if not likely,
that ligand modifications can interfere with CD8 signaling,
which is predicted to adversely affect the function of CD8-
dependent, but not of independent CTL clones.
The present study indicates that generally epitope modi-
fications affect antigen recognition by cloned CD81 CTL
in accordance with changes in TCR–ligand binding. How-
ever, exceptions exist, and from these we learn that factors
other than TCR–ligand binding avidities account for aber-
rant CTL activation. Our data suggest that CD8 can inter-
fere with CTL activation. Because CD8 modulates the ki-
netics of TCR–ligand interactions (27) and by association
with the tyrosine kinase p56lck and the phosphatase CD45
participates in critical phosphorylation/dephosphorylation
events (1, 2, 4, 5, 9, 10, 38), it clearly has the potential to
do so. As CD8 functions are induced by TCR–ligand in-
teractions (36, 37), the interesting possibility is suggested
that epitopes modifications can perturb CTL function via
CD8. Further investigations are clearly needed to elucidate
the role of CD8 and other factors in aberrant CTL func-
tion. The systems described here should greatly facilitate
such future studies as they permit direct assessment of
TCR–ligand binding and kinetics on living cells, as well as
vigorous control of critical experimental parameters.
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